Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Cash from Investing Activities (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Cash from Investing Activities data on record, last reported at -$41000.0 in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 18.0% year-over-year to -$41000.0; the TTM value through Dec 2025 reached -$838000.0, down 142.9%, while the annual FY2025 figure was -$838000.0, 142.9% down from the prior year.
  • Cash from Investing Activities reached -$41000.0 in Q4 2025 per TLSI's latest filing, up from -$176000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $93000.0 in Q2 2025 and bottomed at -$1.6 million in Q3 2022.
  • Average Cash from Investing Activities over 4 years is -$284812.5, with a median of -$70000.0 recorded in 2023.
  • The widest YoY moves for Cash from Investing Activities: up 255.0% in 2025, down 981.82% in 2025.
  • A 4-year view of Cash from Investing Activities shows it stood at -$272000.0 in 2022, then crashed by 36.76% to -$372000.0 in 2023, then skyrocketed by 86.56% to -$50000.0 in 2024, then rose by 18.0% to -$41000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$41000.0 in Q4 2025, -$176000.0 in Q3 2025, and $93000.0 in Q2 2025.